Table 2.
Prevalence of Medical Conditions in the Population with SMI by Measurement Type, Study Population, and Overall
| Overweight | ||||||||||
| Measurement Type | Study Population | Ove rall |
||||||||
| Claims Data (0) |
Clinical Measurement 43-51 (9) |
Self- Rep ort 52-54 (3) |
Othe r (0) |
Inpatient 47,49 (2) |
Outpatient 43,44,46,48,52-54 (7) |
Comm unity45 (1) |
Other 20,21(2) |
Tot al (12) |
||
| Medi an Preval ence |
n/a | 29.5% | 27.8 % |
n/a | 32.7% | 29.0% | 41.4% | 28.0% | 29. 0% |
|
| Mean Preval ence |
n/a | 32.6% | 28.9 % |
n/a | 30.3% | 32.2% | 41.4% | 28.0% | 31. 9% |
|
| Highe st Preval ence |
n/a | 58.0% | 32.0 % |
n/a | 25.0% | 32.0% | 41.4% | 28.0% | 58. 0% |
|
| Lowe st Preval ence |
n/a | 25.0% | 27.8 % |
n/a | 32.7% | 30.0% | 41.4% | 28.0% | 25. 0% |
|
| Obesity | ||||||||||
| Measurement Type | Study Population | Ove rall |
||||||||
| Claims Data (0) |
Clinical Measurement 43,44,46-51,53,57 (10) |
Self- Rep ort 52,54- 56(4) |
Othe r (0) |
Inpatient 17,19,25(3) |
Outpatient 43,44,46,48,52-54,56(8) |
Comm unity55 (1) |
Other 20,21(2) |
Tot al (13) |
||
| Medi an Preval ence |
n/a | 42.0% | 36.3 % |
n/a | 37.0% | 46.2% | 37.8% | 46.0% | 40. 6% |
|
| Mean Preval ence |
n/a | 42.0% | 36.1 % |
n/a | 37.5% | 42.3% | 37.8% | 40.1% | 40. 4% |
|
| Highe st |
n/a | 55.0% | 46.2 % |
n/a | 41.9% | 55.0% | 39.2% | 47.3% | 55. 0% |
|
| Lowe st Preval ence |
n/a | 26.0% | 28.9 % |
n/a | 34.0% | 26.0% | 36.3% | 27.0% | 26. 0% |
|
| Hyperlipidemia | ||||||||||
| Measurement Type | Study Population | Ove rall |
||||||||
| Claims Data 57,60-65 (7) |
Clinical Measurement43,66- 69 (5) |
Self- Rep ort70 (1) |
Othe r 71 |
Inpatient 57,66 (2) |
Outpatient 43,65,68,69,71 (5) |
Comm unity (0) |
Other60
-64,67,70 (7) |
Tot al (14) |
||
| Medi an Preval ence |
28.8% | 11.7% | 14.0 % |
26.0 % |
33.8% | 30.0% | n/a | 24.8% | 26. 6% |
|
| Mean Preval ence |
29.1% | 17.5% | 14.0 % |
26.0 % |
33.8% | 33.9% | n/a | 23.3% | 27. 0% |
|
| Highe st Preval ence |
55.9% | 61.0% | 14.0 % |
26.0 % |
55.9% | 61.0% | n/a | 35.2% | 61. 0% |
|
| Lowe st Preval ence |
12.3% | 10.8% | 14.0 % |
9.0% | 11.7% | 9.0% | n/a | 10.8% | 9.0 % |
|
| Hypertension | ||||||||||
| Measurement Type | Study Population | Ove rall |
||||||||
| Claims Data 57,60-64,73,74 (8) |
Clinical Measurement43,46,4 7,50,65,67,68,75,76,78 (10) |
Self- Rep ort 56,70,77, 81-83 (6) |
Othe r 53,66,71, 79,80 (5) |
Inpatient 47,57,66,73-76 (7) |
Outpatient 43,46,53,56,65,67 ,68,71,77-82 (14) |
Comm unity83 (1) |
Other 50,60-64,70 (7) |
Tot al (29) |
||
| Medi an Preval ence |
35.3% | 37.8% | 24.7 % |
34.0 % |
31.7% | 34.0% | 47.0% | 35.2% | 35. 0% |
|
| Mean Preval ence |
34.7% | 40.9% | 27.8 % |
37.9 % |
34.3% | 37.0% | 47.0% | 34.3% | 35. 8% |
|
| Highe st Preval ence |
61.6% | 68.0% | 47.0 % |
68.0 % |
61.6% | 68.0% | 47.0% | 59.1% | 68. 0% |
|
| Lowe st Preval ence |
10.0% | 14.4% | 20.0 % |
15.9 % |
10.0% | 22.1% | 47.0% | 16.5% | 10. 0% |
|
| Diabetes Mellitus | ||||||||||
| Measurement Type | Study Population | Ove rall |
||||||||
| Claims Data (0) |
Clinical Measurement66,71 (2) |
Self- Rep ort (0) |
Othe r 43,78,79,85 (4) |
Inpatient 66 (1) |
Outpatient 43,71,78,79,85 (5) |
Comm unity (0) |
Other (0) |
Tot al (6) |
||
| Medi an Preval ence |
n/a | 9.2% | n/a | 16.0 % |
6.9% | 13.0% | n/a | n/a | 12. 5% |
|
| Mean Preval ence |
n/a | 9.2% | n/a | 19.5 % |
6.9% | 17.9% | n/a | n/a | 16. 1% |
|
| Highe st Preval ence |
n/a | 11.5% | n/a | 34.0 % |
6.9% | 34.0% | n/a | n/a | 34. 0% |
|
| Lowe st Preval ence |
n/a | 6.9% | n/a | 12.0 % |
6.9% | 11.5% | n/a | n/a | 6.9 % |
|
| Coronary Heart Disease | ||||||||||
| Measurement Type | Study Population | Ove rall |
||||||||
| Claims Data 57,60-63 (5) |
Clinical Measurement (0) |
Self- Rep ort 70,77,8 9 (3) |
Othe r (0) |
Inpatient 57,89 (2) |
Outpatient 77 (1) |
Comm unity (0) |
Other 60-63,70 (5) |
Tot al (8) |
||
| Medi an Preval ence |
5.9% | n/a | 1.0% | n/a | 19.1% | 1.0% | n/a | 5.2% | 5.4 % |
|
| Mean Preval ence |
10.8% | n/a | 12.5 0% |
n/a | 17.2% | 1.0% | n/a | 5.0% | 7.9 % |
|
| Highe st Preval ence |
22.5% | n/a | 140 0.0% |
n/a | 22.5% | 1.0% | n/a | 10.6% | 22. 5% |
|
| Lowe st Preval ence |
2.3% | n/a | 110 0.0% |
n/a | 8.1% | 1.0% | n/a | 1.0% | 1.0 % |
|
| Congestive Heart Failure | ||||||||||
| Measurement Type | Study Population | Ove rall |
||||||||
| Claims Data 61-63 (3) |
Clinical Measurement (0) |
Self- Rep ort77 (1) |
Othe r88 (1) |
Inpatient (0) |
Outpatient 77,88 (2) |
Comm unity (0) |
Other61
-63 (3) |
Tot al (5) |
||
| Medi an Preval ence |
1.5% | n/a | 1.5% | 12.5 % |
n/a | 2.0% | n/a | 1.5% | 1.8 % |
|
| Mean Preval ence |
2.0% | n/a | 1.5% | 12.5 % |
n/a | 5.2% | n/a | 2.0% | 3.6 % |
|
| Highe st Preval ence |
3.2% | n/a | 2.0% | 12.5 % |
n/a | 12.5% | n/a | 3.2% | 12. 5% |
|
| Lowe st Preval ence |
1.2% | n/a | 1.0% | 12.5 % |
n/a | 1.0% | n/a | 1.2% | 1.0 % |
|
| Cerebrovascular Disease | ||||||||||
| Measurement Type | Study Population | Ove rall |
||||||||
| Claims Data 60-64 (5) |
Clinical Measurement (0) |
Self- Rep ort (0) |
Othe r (0) |
Inpatient (0) |
Outpatient (0) |
Comm unity (0) |
Other 60-64 (5) |
Tot al (5) |
||
| Medi an Preval ence |
2.8% | n/a | n/a | n/a | n/a | n/a | n/a | 2.8% | 2.8 % |
|
| Mean Preval ence |
3.1% | n/a | n/a | n/a | n/a | n/a | n/a | 3.1% | 3.1 % |
|
| Highe st Preval ence |
7.8% | n/a | n/a | n/a | n/a | n/a | n/a | 7.8% | 7.8 % |
|
| Lowe st Preval ence |
1.3% | n/a | n/a | n/a | n/a | n/a | n/a | 1.3% | 1.3 % |
|
| Overall Cardiovascular Disease | ||||||||||
| Measurement Type | Study Population | Ove rall |
||||||||
| Claims Data 57,60,64, 73,87 (5) |
Clinical Measurement66 (1) |
Self- Rep ort 56,77,82,83 (4) |
Othe r (0) |
Inpatient 57,66 (2) |
Outpatient 56,77,82,83,87 (5) |
Comm unity (0) |
Other 60,64,73 (3) |
Tot al (10) |
||
| Medi an Preval ence |
22.5% | 4.8% | 9.0% | n/a | 20.9% | 9.6% | n/a | 39.5% | 12. 4% |
|
| Mean Preval ence |
29.8% | 4.8% | 10.5 % |
n/a | 16.1% | 10.5% | n/a | 34.2% | 22. 7% |
|
| Highe st Preval ence |
55.3% | 4.8% | 19.0 % |
n/a | 22.5% | 19.0% | n/a | 55.3% | 55. 3% |
|
| Lowe st Preval ence |
8.8% | 4.8% | 6.0% | n/a | 4.8% | 6.0% | n/a | 8.8% | 4.8 % |
|
| Chronic Obstructive Pulmonary Disease | ||||||||||
| Measurement Type | Study Population | Ove rall |
||||||||
| Claims Data 61-63,87 (4) |
Clinical Measurement (0) |
Self- Rep ort 70,82 (2) |
Othe r (0) |
Inpatient (0) |
Outpatient 82,87 (2) |
Comm unity (0) |
Other 61-63,70 (4) |
Tot al (6) |
||
| Medi an Preval ence |
10.7% | n/a | 4.6% | n/a | n/a | 6.6% | n/a | 10.7% | 8.9 % |
|
| Mean Preval ence |
10.1% | n/a | 4.6% | n/a | n/a | 6.6% | n/a | 9.1% | 8.3 % |
|
| Highe st Preval ence |
12.9% | n/a | 7.1% | n/a | n/a | 7.1% | n/a | 12.9% | 12. 9% |
|
| Lowe st Preval ence |
6.1% | n/a | 2.0% | n/a | n/a | 6.1% | n/a | 2.0% | 2.0 % |
|
| Kidney Disease | ||||||||||
| Measurement Type | Study Population | Ove rall |
||||||||
| Claims Data 61-63 (3) |
Clinical Measurement 75 (1) |
Self- Rep ort77 (1) |
Othe r (0) |
Inpatient 75
(1) |
Outpatient 77
(1) |
Comm unity (0) |
Other 61-63 (3) |
Tot al (5) |
||
| Medi an Preval ence |
1.4% | 0.7% | 3.4% | n/a | 0.7% | 3.4% | n/a | 1.4% | 2.3 % |
|
| Mean Preval ence |
3.2% | 0.7% | 3.4% | n/a | 0.7% | 3.4% | n/a | 3.2% | 3.0 % |
|
| Highe st Preval ence |
6.9% | 0.7% | 3.7% | n/a | 0.7% | 3.7% | n/a | 6.9% | 6.9 % |
|
| Lowe st Preval ence |
0.8% | 0.7% | 3.1% | n/a | 0.7% | 3.1% | n/a | 0.8% | 0.7 % |
|
| Cancer | ||||||||||
| Measurement Type | Study Population | Ove rall |
||||||||
| Claims Data 61,73 (2) |
Clinical Measurement75 (1) |
Self- Rep ort77 (1) |
Othe r (0) |
Inpatient 75 (1) |
Outpatient 77 (1) |
Comm unity (0) |
Other 61,73 (2) |
Tot al (4) |
||
| Medi an Preval ence |
2.2% | 0.4% | 5.2% | n/a | 0.4% | 5.2% | n/a | 2.2% | 2.5 % |
|
| Mean Preval ence |
1.9% | 0.4% | 5.2% | n/a | 0.4% | 5.2% | n/a | 1.9% | 2.7 % |
|
| Highe st Preval ence |
2.8% | 0.4% | 5.2% | n/a | 0.4% | 5.2% | n/a | 2.8% | 5.2 % |
|
| Lowe st Preval ence |
0.6% | 0.4% | 5.2% | n/a | 0.4% | 5.2% | n/a | 0.6% | 0.4 % |
|
| Hepatitis B | ||||||||||
| Measurement Type | Study Population | Ove rall |
||||||||
| Claims Data (0) |
Clinical Measurement 49,95-98 (5) |
Self- Rep ort (0) |
Othe r (0) |
Inpatient 49,95,96 (3) |
Outpatient (0) |
Comm unity (0) |
Other 97,98 (2) |
Tot al (5) |
||
| Medi an Preval ence |
n/a | 20.2% | n/a | n/a | 26.7% | n/a | n/a | 18.9% | 20. 2% |
|
| Mean Preval ence |
n/a | 25.1% | n/a | n/a | 30.3% | n/a | n/a | 19.9% | 25. 1% |
|
| Highe st Preval ence |
n/a | 49.5% | n/a | n/a | 49.5% | n/a | n/a | 29.3% | 49. 5% |
|
| Lowe st Preval ence |
n/a | 12.5% | n/a | n/a | 18.3% | n/a | n/a | 12.5% | 12. 5% |
|
| Hepatitis C | ||||||||||
| Measurement Type | Study Population | Ove rall |
||||||||
| Claims Data 61,63,87, 103,104 (5) |
Clinical Measurement49,95,9 7-102 (8) |
Self- Rep ort 70 (1) |
Othe r (0) |
Inpatient 49,95 (2) |
Outpatient 87 (1) |
Comm unity (0) |
Other 61,63,70,97 -104 (11) |
Tot al (14) |
||
| Medi an Preval ence |
7.1% | 17.2% | 4.0% | n/a | 20.0% | 1.9% | n/a | 10.6% | 12. 3% |
|
| Mean Preval ence |
8.0% | 16.5% | 4.0% | n/a | 20.0% | 1.9% | n/a | 12.2% | 12. 5% |
|
| Highe st Preval ence |
16.5% | 25.4% | 4.0% | n/a | 21.0% | 1.9% | n/a | 25.4% | 25. 4% |
|
| Lowe st Preval ence |
0.7% | 7.1% | 4.0% | n/a | 18.9% | 1.9% | n/a | 0.7% | 0.7 % |
|
| HIV | ||||||||||
| Measurement Type | Study Population | Ove rall |
||||||||
| Claims Data 61,63,87, 103,108- 110 (7) |
Clinical Measurement75,96,9 7 (3) |
Self- Rep ort 70,107 (2) |
Othe r (0) |
Inpatient 75,96 (2) |
Outpatient 70,87,107,108 (4) |
Comm unity (0) |
Other 61,63,97,103 ,109,110 (6) |
Tot al (12) |
||
| Medi an Preval ence |
1.4% | 2.7% | 1.5% | n/a | 3.8% | 1.9% | n/a | 1.6% | 1.8 % |
|
| Mean Preval ence |
1.4% | 3.4% | 1.5% | n/a | 3.8% | 1.9% | n/a | 1.8% | 2.1 % |
|
| Highe st Preval ence |
2.8% | 5.0% | 2.0% | n/a | 4.8% | 2.8% | n/a | 5.0% | 5.0 % |
|
| Lowe st Preval ence |
0.1% | 1.7% | 1.0% | n/a | 2.7% | 1.0% | n/a | 0.1% | 0.1 % |
|